Cedazuridine
TP53 Gene Mutation
The University of Hong KongSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
5 Active assets in the TP53 Gene Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Decitabine Northside Hospital, Inc. | Phase 2 | B |
Azacitidine The University of Hong Kong | Phase 2 | CCC |
Arsenic Trioxide The University of Hong Kong | Phase 2 | CCC |
Epirubicin City of Hope Medical Center | Phase 1 | CC |
Pembrolizumab City of Hope Medical Center | Phase 1 | CC |
Same molecule, other indications
Cedazuridine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →